Orexigen Therapeutics, Inc.
3344 North Torrey Pines Court
Suite 200
La Jolla,
CA 92037
United States - Map
Phone: 858-875-8600
Fax: 858-875-8650
Web Site: http://www.orexigen.com
| Orexigen Therapeutics, Inc., a biopharmaceutical company, focusing on the development of pharmaceutical product candidates for the treatment of obesity. The companys lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. It selected these two product candidates for obesity based research regarding CNS regulation of appetite and energy expenditure, as well as mechanisms in the brain that reinforce unhealthy eating behaviors. Each of these product candidates is a combination of generic drugs that is screened for synergistic CNS activity. Orexigen Therapeutics was founded in 2002 and is headquartered in La Jolla, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Eckard Weber M.D., 57
Co-Founder and Non Exec. Chairman |
$
25.00K |
$
0 | Mr. Graham K. Cooper , 40
Chief Financial Officer, Principal Accounting Officer and Treasurer |
$
447.00K |
$
93.00K | Dr. Eduardo Dunayevich M.D., 44
Chief Medical Officer |
$
458.00K |
$
82.00K | Ms. Heather D. Turner J.D., 37
VP, Sec. and Gen. Counsel |
$
397.00K |
$
0 | Dr. Ronald P. Landbloom M.D., 63
VP of Clinical Devel. |
$
363.00K |
$
416.00K |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.52% Nasdaq 0.00%
Profile
